The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Open accessAbstract
BACKGROUND: In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension. METHODS: In this event-driven, phase 3, randomized, double-blind, placebo-controlled trial, we randomly assigned 1156 patients with pulmonary arterial hypertension to receive placebo or selexipag in individualized doses (maximum dose, 1600 μg twice daily). Patients were eligible for enrollment if they were not receiving treatment for pulmonary arterial hypertension or if they were receiving a stable dose of an endothelin-receptor antagonist, a phosphodiesterase type 5 inhibitor, or both. The primary end point was a composite of death from any cause or a complication related to pulmonary arterial hypertension up to the end of the treatment period (defined for each patient as 7 days after the date of the last intake of selexipag or placebo). RESULTS: A primary end-point event occurred in 397 patients--41.6% of those in the placebo group and 27.0% of those in the selexipag group (hazard ratio in the selexipag group as compared with the placebo group, 0.60; 99% confidence interval, 0.46 to 0.78; P<0.001). Disease progression and hospitalization accounted for 81.9% of the events. The effect of selexipag with respect to the primary end point was similar in the subgroup of patients who were not receiving treatment for the disease at baseline and in the subgroup of patients who were already receiving treatment at baseline (including those who were receiving a combination of two therapies). By the end of the study, 105 patients in the placebo group and 100 patients in the selexipag group had died from any cause. Overall, 7.1% of patients in the placebo group and 14.3% of patients in the selexipag group discontinued their assigned regimen prematurely because of adverse events. The most common adverse events in the selexipag group were consistent with the known side effects of prostacyclin, including headache, diarrhea, nausea, and jaw pain. CONCLUSIONS: Among patients with pulmonary arterial hypertension, the risk of the primary composite end point of death or a complication related to pulmonary arterial hypertension was significantly lower with selexipag than with placebo. There was no significant difference in mortality between the two study groups. (Funded by Actelion Pharmaceuticals; GRIPHON ClinicalTrials.gov number, NCT01106014.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Authors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Moncada, S., Gryglewski, R., Bunting, S., & Vane, J. R. (1976) · Nature · doi:10.1038/263663a0 · Cited by 3,595
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationBarst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Self-citationProstanoid Receptors: Structures, Properties, and Functions
Narumiya, S., Sugimoto, Y., & Ushikubi, F. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1193 · Cited by 2,412
Pulmonary Arterial Hypertension in France: Results from a National Registry
Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaici, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200510-1668oc · Cited by 2,000
Self-citationInhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783
Self-citationColeman, R. A., Smith, W. L., & Narumiya, S. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06784-5 · Cited by 1,735
Treatment of Pulmonary Arterial Hypertension
Humbert, M., Sitbon, O., & Simonneau, G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040291 · Cited by 1,707
Self-citationPulmonary Arterial Hypertension
Farber, H. W., & Loscalzo, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035488 · Cited by 1,463
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H.-A., Jansa, P., Jing, Z.-C., Le Brun, F.-O., Mehta, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213917 · Cited by 1,443
Self-citationSIMONNEAU, G., BARST, R. J., GALIE, N., NAEIJE, R., RICH, S., BOURGE, R. C., KEOGH, A., OUDIZ, R., FROST, A., BLACKBURN, S. D., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.6.2106079 · Cited by 1,441
Self-citationRiociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Ghofrani, H.-A., D'Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209657 · Cited by 1,401
Self-citationHumbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaïci, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.911818 · Cited by 1,399
Self-citationRiociguat for the treatment of pulmonary arterial hypertension
Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209655 · Cited by 1,346
Self-citationChristman, B. W., McPherson, C. D., Newman, J. H., King, G. A., Bernard, G. R., Groves, B. M., & Loyd, J. E. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270202 · Cited by 1,187
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Galiè, N., Barberà, J. A., Frost, A. E., Ghofrani, H.-A., Hoeper, M. M., McLaughlin, V. V., Peacock, A. J., Simonneau, G., Vachiery, J.-L., Grünig, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413687 · Cited by 1,182
Self-citationBenza, R. L., Miller, D. P., Barst, R. J., Badesch, D. B., Frost, A. E., & McGoon, M. D. (2012) · Chest · doi:10.1378/chest.11-1460 · Cited by 1,104
Tadalafil Therapy for Pulmonary Arterial Hypertension
Galiè, N., Brundage, B. H., Ghofrani, H. A., Oudiz, R. J., Simonneau, G., Safdar, Z., Shapiro, S., White, R. J., Chan, M., Beardsworth, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.839274 · Cited by 1,103
Self-citationGaliè, N., Torbicki, A., Barst, R. J., Dartevelle, P., Haworth, S. G., Higenbottam, T., Olschewski, H., Peacock, A. J., Pietra, G., Rubin, L. J., et al. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.09.014 · Cited by 1,053
Self-citationProstanoid Receptors: Subtypes and Signaling
Breyer, R. M., Bagdassarian, C. K., Myers, S. A., & Breyer, M. D. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.661 · Cited by 1,011
Hata, A. N., & Breyer, R. M. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.06.003 · Cited by 840
TUDER, R. M., COOL, C. D., GERACI, M. W., WANG, J., ABMAN, S. H., WRIGHT, L., BADESCH, D., & VOELKEL, N. F. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.6.9804054 · Cited by 806
Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., Ichikawa, A., Aze, Y., Tanaka, T., Yoshida, N., et al. (1997) · Nature · doi:10.1038/41780 · Cited by 773
Rubin, L. J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W. B., Diehl, J. H., Crow, J., & Long, W. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-7-485 · Cited by 706
Self-citationUpdated Treatment Algorithm of Pulmonary Arterial Hypertension
Galiè, N., Corris, P. A., Frost, A., Girgis, R. E., Granton, J., Jing, Z. C., Klepetko, W., McGoon, M. D., McLaughlin, V. V., Preston, I. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.031 · Cited by 667
Self-citationGaliè, N., Humbert, M., Vachiéry, J.-L., Vizza, C., Kneussl, M., Manes, A., Sitbon, O., Torbicki, A., Delcroix, M., Naeije, R., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01786-2 · Cited by 648
Self-citationBeraprost therapy for pulmonary arterial hypertension
Barst, R. J., McGoon, M., McLaughlin, V., Tapson, V., Oudiz, R., Shapiro, S., Robbins, I. M., Channick, R., Badesch, D., Rayburn, B. K., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00463-7 · Cited by 631
Self-citationRandomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension
McLaughlin, V. V., Oudiz, R. J., Frost, A., Tapson, V. F., Murali, S., Channick, R. N., Badesch, D. B., Barst, R. J., Hsu, H. H., & Rubin, L. J. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200603-358oc · Cited by 626
Self-citationAddition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension
McLaughlin, V. V., Benza, R. L., Rubin, L. J., Channick, R. N., Voswinckel, R., Tapson, V. F., Robbins, I. M., Olschewski, H., Rubenfire, M., & Seeger, W. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.027 · Cited by 566
Self-citationAbramovitz, M., Adam, M., Boie, Y., Carrière, M.-C., Denis, D., Godbout, C., Lamontagne, S., Rochette, C., Sawyer, N., Tremblay, N. M., et al. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00164-x · Cited by 557
Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension
Barst, R. J., Gibbs, J. S. R., Ghofrani, H. A., Hoeper, M. M., McLaughlin, V. V., Rubin, L. J., Sitbon, O., Tapson, V. F., & Galiè, N. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.017 · Cited by 499
Self-citationWoodward, D. F., Jones, R. L., & Narumiya, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003517 · Cited by 443
Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis
OLSCHEWSKI, H., ARDESCHIR GHOFRANI, H., WALMRATH, D., SCHERMULY, R., TEMMESFELD-WOLLBRÜCK, B., GRIMMINGER, F., & SEEGER, W. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.2.9810008 · Cited by 410
Regan, J. W., Bailey, T. J., Pepperl, D. J., Pierce, K. L., Bogardus, A. M., Donello, J. E., Fairbairn, C. E., Kedzie, K. M., Woodward, D. F., & Gil, D. W. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09674-9 · Cited by 390
Prostanoids and prostanoid receptors in signal transduction
Bos, C. L., Richel, D. J., Ritsema, T., Peppelenbosch, M. P., & Versteeg, H. H. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2003.08.006 · Cited by 387
Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study
Sitbon, O., Jaïs, X., Savale, L., Cottin, V., Bergot, E., Macari, E. A., Bouvaist, H., Dauphin, C., Picard, F., Bulifon, S., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00116313 · Cited by 382
Self-citationTapson, V. F., Torres, F., Kermeen, F., Keogh, A. M., Allen, R. P., Frantz, R. P., Badesch, D. B., Frost, A. E., Shapiro, S. M., Laliberte, K., et al. (2012) · Chest · doi:10.1378/chest.11-2212 · Cited by 378
Self-citationLong-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Barst, R. J., Galie, N., Naeije, R., Simonneau, G., Jeffs, R., Arneson, C., & Rubin, L. J. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00044406 · Cited by 338
Self-citationJing, Z.-C., Parikh, K., Pulido, T., Jerjes-Sanchez, C., White, R. J., Allen, R., Torbicki, A., Xu, K.-F., Yehle, D., Laliberte, K., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.124388 · Cited by 326
Self-citationThe role of prostacyclin in vascular tissue.
Moncada, S., & Vane, J. R. (1979) · PubMed · Cited by 316
Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.
Rubin, L. J., Groves, B. M., Reeves, J. T., Frosolono, M., Handel, F., & Cato, A. E. (1982) · Circulation · doi:10.1161/01.cir.66.2.334 · Cited by 316
Self-citationSimonneau, G., Torbicki, A., Hoeper, M. M., Delcroix, M., Karlócai, K., Galiè, N., Degano, B., Bonderman, D., Kurzyna, M., Efficace, M., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00137511 · Cited by 314
Self-citationCloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype.
Funk, C. D., Furci, L., FitzGerald, G. A., Grygorczyk, R., Rochette, C., Bayne, M. A., Abramovitz, M., Adam, M., & Metters, K. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74379-8 · Cited by 310
Tapson, V. F., Jing, Z.-C., Xu, K.-F., Pan, L., Feldman, J., Kiely, D. G., Kotlyar, E., McSwain, C. S., Laliberte, K., Arneson, C., et al. (2013) · Chest · doi:10.1378/chest.12-2875 · Cited by 297
Self-citationSafety and Efficacy of IV Treprostinil for Pulmonary Arterial Hypertension
Tapson, V. F., Gomberg-Maitland, M., McLaughlin, V. V., Benza, R. L., Widlitz, A. C., Krichman, A., & Barst, R. J. (2006) · Chest · doi:10.1378/chest.129.3.683 · Cited by 294
Self-citationProstacyclin therapies for the treatment of pulmonary arterial hypertension
Gomberg-Maitland, M., & Olschewski, H. (2008) · European Respiratory Journal · doi:10.1183/09031936.00097107 · Cited by 291
Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial
Olschewski, H., Ghofrani, H. A., Schmehl, T., Winkler, J., Wilkens, H., Hoeper, M. M., Behr, J., Kleber, F. X., Seeger, W., & for the German PPH Study Group* (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-6-200003210-00003 · Cited by 286
Self-citationAerosolised prostacyclin in adult respiratory distress syndrome
WALMRATH, D., Schneider, T. L., Pilch, J., Grimminger, F., & Seeger, W. (1993) · The Lancet · doi:10.1016/0140-6736(93)92004-d · Cited by 284
End Points and Clinical Trial Design in Pulmonary Arterial Hypertension
McLaughlin, V. V., Badesch, D. B., Delcroix, M., Fleming, T. R., Gaine, S. P., Galiè, N., Gibbs, J. S. R., Kim, N. H., Oudiz, R. J., Peacock, A., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.007 · Cited by 251
Self-citationProstaglandin E2receptor distribution and function in the gastrointestinal tract
Dey, I., Lejeune, M., & Chadee, K. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706923 · Cited by 250
Clapp, L. H., Finney, P. A., Turcato, S., Tran, S., Rubin, L. J., & Tinker, A. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.26.2.4695 · Cited by 235
Self-citationEfficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension
McLaughlin, V. V., Gaine, S. P., Barst, R. J., Oudiz, R. J., Bourge, R. C., Frost, A., Robbins, I. M., Tapson, V. F., McGoon, M. D., Badesch, D. B., et al. (2003) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200302000-00019 · Cited by 232
Self-citationProstanoid therapy for pulmonary arterial hypertension
Badesch, D. B., McLaughlin, V. V., Delcroix, M., Vizza, C. D., Olschewski, H., Sitbon, O., & Barst, R. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.036 · Cited by 228
Self-citationEfficacy of Long-term Subcutaneous Treprostinil Sodium Therapy in Pulmonary Hypertension
Lang, I., Gomez-Sanchez, M., Kneussl, M., Naeije, R., Escribano, P., Skoro-Sajer, N., & Vachiery, J.-L. (2006) · Chest · doi:10.1378/chest.129.6.1636 · Cited by 203
Self-citationRajkumar, R., Konishi, K., Richards, T. J., Ishizawar, D. C., Wiechert, A. C., Kaminski, N., & Ahmad, F. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00254.2009 · Cited by 196
Prostacyclin among prostanoids.
Gryglewski, R. J. (2008) · PubMed · Cited by 193
Whittle, B. J., Silverstein, A. M., Mottola, D. M., & Clapp, L. H. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.03.012 · Cited by 168
A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension
Mubarak, K. K. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2009.07.015 · Cited by 165
The molecular targets of approved treatments for pulmonary arterial hypertension
Humbert, M. J. C., & Ghofrani, H. A. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-207170 · Cited by 164
Self-citationKuwano, K., Hashino, A., Asaki, T., Hamamoto, T., Yamada, T., Okubo, K., & Kuwabara, K. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.124248 · Cited by 164
Prostanoids for Pulmonary Arterial Hypertension
Galiè, N., Manes, A., & Branzi, A. (2003) · American Journal of Respiratory Medicine · doi:10.1007/bf03256644 · Cited by 162
Self-citationWharton, J., Davie, N. J., Upton, P. D., Yacoub, M. H., Polak, J. M., & Morrell, N. W. (2000) · Circulation · doi:10.1161/01.cir.102.25.3130 · Cited by 148
DeWitt, D. L., Day, J. S., Sonnenburg, W. K., & Smith, W. L. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111151 · Cited by 147
Prostanoid Receptors in the Human Vascular Wall
Norel, X. (2007) · The Scientific World JOURNAL · doi:10.1100/tsw.2007.184 · Cited by 142
Prostacyclin: A Vascular Mediator
Vane, J. R., & Corin, R. E. (2003) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/s1078-5884(03)00385-x · Cited by 138
Contemporary Trends in the Diagnosis and Management of Pulmonary Arterial Hypertension
McLaughlin, V. V., Langer, A., Tan, M., Clements, P. J., Oudiz, R. J., Tapson, V. F., Channick, R. N., & Rubin, L. J. (2013) · CHEST Journal · doi:10.1378/chest.11-3060 · Cited by 129
Self-citationForest plots and the interpretation of subgroups
Cuzick, J. M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61026-4 · Cited by 126
Alfranca, A., Iñiguez, M. A., Fresno, M., & Redondo, J. M. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.12.020 · Cited by 118
Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension
Lang, I. M., & Gaine, S. (2015) · European Respiratory Review · doi:10.1183/16000617.0067-2015 · Cited by 101
Self-citationClapp, L. H., & Gurung, R. (2015) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2015.04.007 · Cited by 97
Farber, H. W., Miller, D. P., Meltzer, L. A., & McGoon, M. D. (2013) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2013.08.010 · Cited by 93
Long-term outcome with intravenous iloprost in pulmonary arterial hypertension
Hoeper, M. M., Gall, H. J., Seyfarth, H.-J., Halank, M., Ghofrani, H. A., Winkler, J., Golpon, H. A., Olsson, K. M., Nickel, N. P., Opitz, C. F., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00130408 · Cited by 93
Self-citationInternalization and Sequestration of the Human Prostacyclin Receptor
Smyth, E. M., Austin, S. C., Reilly, M. P., & FitzGerald, G. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003873200 · Cited by 90
Prostanoid EP1‐ and TP‐receptors involved in the contraction of human pulmonary veins
Walch, L., de Montpréville, V., Brink, C., & Norel, X. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704423 · Cited by 74
Li, R.-C., Cindrová‐Davies, T., Skepper, J. N., & Sellers, L. A. (2004) · Circulation Research · doi:10.1161/01.res.0000121568.40692.97 · Cited by 71
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
Kaufmann, P., Okubo, K., Bruderer, S., Mant, T., Yamada, T., Dingemanse, J., & Mukai, H. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0117-4 · Cited by 69
Kitterman, N., Poms, A. D., Miller, D. P., Lombardi, S., Farber, H. W., & Barst, R. J. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.05.014 · Cited by 64
Selexipag: A Selective Prostacyclin Receptor Agonist that Does Not Affect Rat Gastric Function
Morrison, K., Ernst, R., Hess, P., Studer, R. O., & Clozel, M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.169748 · Cited by 64
Bruderer, S., Hurst, N., Kaufmann, P., & Dingemanse, J. (2014) · Pharmacology · doi:10.1159/000367630 · Cited by 58
Rich, J. D., Glassner, C., Wade, M., Coslet, S., Arneson, C. P., Doran, A. K., & Gomberg‐Maitland, M. (2011) · CHEST Journal · doi:10.1378/chest.11-0245 · Cited by 58
Benyahia, C., Boukais, K., Gomez, I., Silverstein, A. M., Clapp, L. H., Fabre, A., Danel, C. J., Lesèche, G., Longrois, D., & Norel, X. (2013) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2013.07.001 · Cited by 54
Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs
Zardi, E. M., Zardi, D. M., Cacciapaglia, F., Dobrina, A., Amoroso, A., Picardi, A., & Afeltra, A. (2004) · International Immunopharmacology · doi:10.1016/j.intimp.2004.10.016 · Cited by 50
Sobolewski, A., Jourdan, K. B., Upton, P. D., Long, L., & Morrell, N. W. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00270.2003 · Cited by 29
Nonprostanoid prostacyclin mimetics. 3. Structural variations of the diphenyl heterocycle moiety
Meanwell, N. A., Rosenfeld, M. J., Trehan, A. K., et al. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00097a007 · Cited by 28
Jones, R. D., Thompson, J. S., & Morice, A. H. (1997) · Pulmonary Pharmacology & Therapeutics · doi:10.1006/pupt.1997.0071 · Cited by 16
Cited by
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citation2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 3,975
Self-citation2020 ESC Guidelines for the management of adult congenital heart disease
Baumgartner, H., De Backer, J., Babu-Narayan, S. V., Budts, W., Chessa, M., Diller, G.-P., lung, B., Kluin, J., Lang, I. M., Meijboom, F., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa554 · Cited by 2,311
Self-citation
Metadata
- Authors
- Sitbon, O., Channick, R., Chin, K. M., Frey, A., Gaine, S., Galiè, N., Ghofrani, H.-A., Hoeper, M. M., Lang, I. M., Preiss, R., Rubin, L. J., Di Scala, L., Tapson, V., Adzerikho, I., Liu, J., Moiseeva, O., Zeng, X., Simonneau, G., & McLaughlin, V. V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-12-24
- Volume
- 373
- Issue
- 26
- Pages
- 2522-2533
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2278696749
- Cited by
- 1,060
- References
- 90
- FWCI
- 68.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.